Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...

Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

Here are two brilliant options along those lines: CVS Health (NYSE: CVS) and Bristol Myers Squibb (NYSE: BMY). Find out why, ...

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

Gabriele Ricci, chief data and technology officer, has been reorganizing the technology function at Takeda Pharmaceutical.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $59.02 which represents a decrease of $-0.80 or -1.34% from the prior close of $59.82. The stock opened at $59.82 and ...

Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...

Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...